Virus-like nanoparticles (VLPs) based technology in the development of breast cancer ‎vaccines‎. (December 2022)

• Record Type: Journal Article
• Authors: Arab, Atefeh; Nikpoor, Amin Reza; Asadi, Peyman; Iraei, Reza; Yazdian-Robati, Rezvan; Sheikh, Afsana; Kesharwani, Prashant
• Is Part Of: Process biochemistry. Volume 123(2022)
• Page Start: 44
• Page End: 51
• Publication Date: 2022-12
• Subjects: Virus-like particle -- Vaccine -- Breast cancer -- Humoral immunity -- Cellular immunity -- Complement system; Biochemical engineering -- Periodicals; Biotechnology -- Periodicals; Biochemistry -- periodicals; Biotechnology -- periodicals; Chemical Engineering -- periodicals; Génie biochimique -- Périodiques; Biotechnologie -- Périodiques; Biochemical engineering; Biotechnology; Periodicals; 660.63
• DOI: 10.1016/j.procbio.2022.10.020
• Languages: English
• ISSNs: 1359-5113

Abstract

Abstract: Virus-like nanoparticles (VLPs) resemble structures of viruses that are devoid of the viral genome, which are widely exerted in vaccine designs, especially cancer vaccines. These particles can trigger both humoral and cellular immunity due to their particular nature and repetitive structure. The average diameter size of most VLPs is in the range of 20–200 nm, which provides easy draining into lymphatic vessels for stimulating the immune system without requiring any adjuvants. Many investigations focused on the task of designing vaccines based on VLPs to improve their efficacy for prophylactic and therapeutic applications throughout cancer treatments. In this review, we discussed the recent developments of VLPs based technology in regard to breast cancer. Graphical Abstract: ga1 Highlights: Virus-like nanoparticles (VLNPs) resemble structures of viruses that are devoid of the viral genome. VLNPs are widely exerted in vaccine designs, especially cancer vaccines. VLNPs provides their effortless draining into lymphatic vessels for stimulating the immune system. We discussed the recent developments of VLNPs based technology in regards to breast cancer.